{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:31:21Z","timestamp":1792042281027,"version":"4.4.0"},"reference-count":56,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2020,10,23]]},"DOI":"10.1253\/circj.cj-20-0703","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T22:06:44Z","timestamp":1599516404000},"page":"1895-1902","source":"Crossref","is-referenced-by-count":13,"title":["Future Directions of Therapeutic Vaccines for Chronic Diseases"],"prefix":"10.1253","volume":"84","author":[{"given":"Ryo","family":"Nakamaru","sequence":"first","affiliation":[{"name":"Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine"},{"name":"Department of Health Development and Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Nakagami","sequence":"additional","affiliation":[{"name":"Department of Health Development and Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Rakugi","sequence":"additional","affiliation":[{"name":"Department of Geriatric and General Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Clinical Gene Therapy, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Delavall\u00e9e L, Duvallet E, Semerano L, Assier E, Boissier MC. Anticytokine vaccination in autoimmune diseases. <i>Swiss Med Wkly<\/i> 2010; 140: w13108.","DOI":"10.4414\/smw.2010.13108"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Dillman RO. Cancer immunotherapy. <i>Cancer Biother Radiopharm<\/i> 2011; 26: 1\u201364.","DOI":"10.1089\/cbr.2010.0902"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer\u2019s disease. <i>Nature<\/i> 2000; 408: 982\u2013985.","DOI":"10.1038\/35050116"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Schenk D. Amyloid-beta immunotherapy for Alzheimer\u2019s disease: The end of the beginning. <i>Nat Rev Neurosci<\/i> 2002; 3: 824\u2013828.","DOI":"10.1038\/nrn938"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. <i>Nature<\/i> 1999; 400: 173\u2013177.","DOI":"10.1038\/22124"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: A double-blind, randomised, placebo-controlled phase IIa study. <i>Lancet<\/i> 2008; 371: 821\u2013827.","DOI":"10.1016\/S0140-6736(08)60381-5"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kawakami R, Nozato Y, Nakagami H, Ikeda Y, Shimamura M, Yoshida S, et al. Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice. <i>PLoS One<\/i> 2018; 13: e0191895.","DOI":"10.1371\/journal.pone.0191895"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Dyer MR, Renner WA, Bachmann MF. A second vaccine revolution for the new epidemics of the 21st century. <i>Drug Discov Today<\/i> 2006; 11: 1028\u20131033.","DOI":"10.1016\/j.drudis.2006.09.006"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. <i>Science<\/i> 2003; 301: 1374\u20131377.","DOI":"10.1126\/science.1086907"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Nakagami H. Design of therapeutic vaccines as a novel antibody therapy for cardiovascular diseases. <i>J Cardiol<\/i> 2017; 70: 201\u2013205.","DOI":"10.1016\/j.jjcc.2017.01.010"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): A biomedical review. <i>Micron<\/i> 1999; 30: 597\u2013623.","DOI":"10.1016\/S0968-4328(99)00036-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Nakagami F, Koriyama H, Nakagami H, Osako MK, Shimamura M, Kyutoku M, et al. Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. <i>PLoS One<\/i> 2013; 8: e60493.","DOI":"10.1371\/journal.pone.0060493"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Nakagami H, Morishita R. Recent advances in therapeutic vaccines to treat hypertension. <i>Hypertension<\/i> 2018; 72: 1031\u20131036.","DOI":"10.1161\/HYPERTENSIONAHA.118.11084"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Wakerlin GE. Antibodies to renin as proof of the pathogenesis of sustained renal hypertension. <i>Circulation<\/i> 1958; 17: 653\u2013657.","DOI":"10.1161\/01.CIR.17.4.653"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Deodhar SD, Haas E, Goldblatt H. Production of antirenin to homologous renin and its effect of experimental renal hypertension. <i>J Exp Med<\/i> 1964; 119: 425\u2013432.","DOI":"10.1084\/jem.119.3.425"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Michel JB, Guettier C, Philippe M, Galen FX, Corvol P, M\u00e9nard J. Active immunization against renin in normotensive marmoset. <i>Proc Natl Acad Sci USA<\/i> 1987; 84: 4346\u20134350.","DOI":"10.1073\/pnas.84.12.4346"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Michel JB, Sayah S, Guettier C, Nussberger J, Philippe M, Gonzalez MF, et al. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. <i>Circulation<\/i> 1990; 81: 1899\u20131910.","DOI":"10.1161\/01.CIR.81.6.1899"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Qiu Z, Chen X, Zhou Y, Lin J, Ding D, Yang S, et al. Therapeutic vaccines against human and rat renin in spontaneously hypertensive rats. <i>PLoS One<\/i> 2013; 8: e66420.","DOI":"10.1371\/journal.pone.0066420"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Gardiner SM, Auton TR, Downham MR, Sharp HL, Kemp PA, March JE, et al. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. <i>Br J Pharmacol<\/i> 2000; 129: 1178\u20131182.","DOI":"10.1038\/sj.bjp.0703178"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Downham MR, Auton TR, Rosul A, Sharp HL, Sj\u00f6str\u00f6m L, Rushton A, et al. Evaluation of two carrier protein-angiotensin I conjugate vaccines to assess their future potential to control high blood pressure (hypertension) in man. <i>Br J Clin Pharmacol<\/i> 2003; 56: 505\u2013512.","DOI":"10.1046\/j.1365-2125.2003.01926.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Brown MJ, Coltart J, Gunewardena K, Ritter JM, Auton TR, Glover JF. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. <i>Clin Sci (Lond)<\/i> 2004; 107: 167\u2013173.","DOI":"10.1042\/CS20030381"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Amb\u00fchl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, et al. A vaccine for hypertension based on virus-like particles: Preclinical efficacy and phase I safety and immunogenicity. <i>J Hypertens<\/i> 2007; 25: 63\u201372.","DOI":"10.1097\/HJH.0b013e32800ff5d6"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Koriyama H, Nakagami H, Nakagami F, Osako MK, Kyutoku M, Shimamura M, et al. Long-term reduction of high blood pressure by angiotensin II DNA vaccine in spontaneously hypertensive rats. <i>Hypertension<\/i> 2015; 66: 167\u2013174.","DOI":"10.1161\/HYPERTENSIONAHA.114.04534"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Pumpens P, Grens E. HBV core particles as a carrier for B cell\/T cell epitopes. <i>Intervirology<\/i> 2001; 44: 98\u2013114.","DOI":"10.1159\/000050037"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Watanabe R, Suzuki JI, Wakayama K, Maejima Y, Shimamura M, Koriyama H, et al. A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. <i>Sci Rep<\/i> 2017; 7: 43920.","DOI":"10.1038\/srep43920"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Wakayama K, Shimamura M, Suzuki JI, Watanabe R, Koriyama H, Akazawa H, et al. Angiotensin II peptide vaccine protects ischemic brain through reducing oxidative stress. <i>Stroke<\/i> 2017; 48: 1362\u20131368.","DOI":"10.1161\/STROKEAHA.116.016269"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: A double-blind, randomised, placebo-controlled phase IIa study. <i>Lancet<\/i> 2008; 371: 821\u2013827.","DOI":"10.1016\/S0140-6736(08)60381-5"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Chen X, Qiu Z, Yang S, Ding D, Chen F, Zhou Y, et al. Effectiveness and safety of a therapeutic vaccine against angiotensin II receptor type 1 in hypertensive animals. <i>Hypertension<\/i> 2013; 61: 408\u2013416.","DOI":"10.1161\/HYPERTENSIONAHA.112.201020"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Camelia BG, Sadashiva K. Model of the whole rat AT1 receptor and the ligand-binding site. <i>J Mol Model<\/i> 2006; 12: 325\u2013337.","DOI":"10.1007\/s00894-005-0049-z"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Fierens FL, Vanderheyden PM, De Backer JP, Vauquelin G. Insurmountable angiotensin AT1 receptor antagonists: The role of tight antagonist binding. <i>Eur J Pharmacol<\/i> 1999; 372: 199\u2013206.","DOI":"10.1016\/S0014-2999(99)00205-8"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Burnier M. Angiotensin II type 1 receptor blockers. <i>Circulation<\/i> 2001; 103: 904\u2013912.","DOI":"10.1161\/01.CIR.103.6.904"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Azegami T, Sasamura H, Hayashi K, Itoh H. Vaccination against the angiotensin type 1 receptor for the prevention of L-NAME-induced nephropathy. <i>Hypertens Res<\/i> 2012; 35: 492\u2013499.","DOI":"10.1038\/hr.2011.212"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Ding D, Du Y, Qiu Z, Yan S, Chen F, Wang M, et al. Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy. <i>J Mol Med (Berl)<\/i> 2016; 94: 207\u2013218.","DOI":"10.1007\/s00109-015-1343-6"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Pan Y, Zhou Z, Zhang H, Zhou Y, Li Y, Li C, et al. The ATRQ\u03b2-001 vaccine improves cardiac function and prevents postinfarction cardiac remodeling in mice. <i>Hypertens Res<\/i> 2019; 42: 329\u2013340.","DOI":"10.1038\/s41440-018-0185-3"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Zhang H, Liao M, Cao M, Qiu Z, Yan X, Zhou Y, et al. ATRQ\u03b2-001 vaccine prevents experimental abdominal aortic aneurysms. <i>J Am Heart Assoc<\/i> 2019; 8: e012341.","DOI":"10.1161\/JAHA.119.012341"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, J\u00fcpner A, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. <i>J Clin Invest<\/i> 1999; 103: 945\u2013952.","DOI":"10.1172\/JCI4106"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Dragun D, M\u00fcller DN, Br\u00e4sen JH, Fritsche L, Nieminen-Kelh\u00e4 M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. <i>N Engl J Med<\/i> 2005; 352: 558\u2013569.","DOI":"10.1056\/NEJMoa035717"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Rossitto G, Regolisti G, Rossi E, Negro A, Nicoli D, Casali B, et al. Elevation of angiotensin-II type-1-receptor autoantibodies titer in primary aldosteronism as a result of aldosterone-producing adenoma. <i>Hypertension<\/i> 2013; 61: 526\u2013533.","DOI":"10.1161\/HYPERTENSIONAHA.112.202945"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Kem DC, Li H, Velarde-Miranda C, Liles C, Vanderlinde-Wood M, Galloway A, et al. Autoimmune mechanisms activating the angiotensin AT1 receptor in \u2018primary\u2019 aldosteronism. <i>J Clin Endocrinol Metab<\/i> 2014; 99: 1790\u20131797.","DOI":"10.1210\/jc.2013-3282"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Williams TA, Jaquin D, Burrello J, Philippe A, Yang Y, Rank P, et al. Diverse responses of autoantibodies to the angiotensin II type 1 Receptor in primary aldosteronism. <i>Hypertension<\/i> 2019; 74: 784\u2013792.","DOI":"10.1161\/HYPERTENSIONAHA.119.13156"},{"key":"41","unstructured":"41. Piazza M, Seccia TM, Caroccia B, Rossitto G, Scarpa R, Persichitti P, et al. AT1AA (angiotensin II type-1 receptor autoantibodies): Cause or consequence of human primary aldosteronism? <i>Hypertension<\/i> 2019; 74: 793\u2013799."},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Wu H, Wang Y, Wang G, Qiu Z, Hu X, Zhang H, et al. A bivalent antihypertensive vaccine targeting L-type calcium channels and angiotensin AT1 receptors. <i>Br J Pharmacol<\/i> 2020; 177: 402\u2013419.","DOI":"10.1111\/bph.14875"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Xu SZ, Zeng F, Lei M, Li J, Gao B, Xiong C, et al. Generation of functional ion-channel tools by E3 targeting. <i>Nat Biotechnol<\/i> 2005; 23: 1289\u20131293.","DOI":"10.1038\/nbt1148"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Tang L, Gamal El-Din TM, Swanson TM, Pryde DC, Scheuer T, Zheng N, et al. Structural basis for inhibition of a voltage-gated Ca2+ channel by Ca2+ antagonist drugs. <i>Nature<\/i> 2016; 537: 117\u2013121.","DOI":"10.1038\/nature19102"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Pang Z, Nakagami H, Osako MK, Koriyama H, Nakagami F, Tomioka H, et al. Therapeutic vaccine against DPP4 improves glucose metabolism in mice. <i>Proc Natl Acad Sci USA<\/i> 2014; 111: E1256\u2013E1263.","DOI":"10.1073\/pnas.1322009111"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. <i>N Engl J Med<\/i> 2012; 367: 1891\u20131900.","DOI":"10.1056\/NEJMoa1201832"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet<\/i> 2012; 380: 1995\u20132006.","DOI":"10.1016\/S0140-6736(12)61771-1"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Landlinger C, Pouwer MG, Juno C, van der Hoorn JWA, Pieterman EJ, Jukema JW, et al. The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice. <i>Eur Heart J<\/i> 2017; 38: 2499\u20132507.","DOI":"10.1093\/eurheartj\/ehx260"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Pan Y, Zhou Y, Wu H, Chen X, Hu X, Zhang H, Zhou Z, et al. A therapeutic peptide vaccine against PCSK9. <i>Sci Rep<\/i> 2017; 7: 12534.","DOI":"10.1038\/s41598-017-13069-w"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Yoshida S, Nakagami H, Hayashi H, Ikeda Y, Sun J, Tenma A, et al. The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. <i>Nat Commun<\/i> 2020; 11: 2482.","DOI":"10.1038\/s41467-020-16347-w"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Goronzy JJ, Weyand CM. Immune aging and autoimmunity. <i>Cell Mol Life Sci<\/i> 2012; 69: 1615\u20131623.","DOI":"10.1007\/s00018-012-0970-0"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Campisi J. Aging, cellular senescence, and cancer. <i>Annu Rev Physiol<\/i> 2013; 75: 685\u2013705.","DOI":"10.1146\/annurev-physiol-030212-183653"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. van Deursen JM. The role of senescent cells in ageing. <i>Nature<\/i> 2014; 509: 439\u2013446.","DOI":"10.1038\/nature13193"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Copp\u00e9 JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: The dark side of tumor suppression. <i>Annu Rev Pathol<\/i> 2010; 5: 99\u2013118.","DOI":"10.1146\/annurev-pathol-121808-102144"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Childs BG, Durik M, Baker DJ, van Deursen JM. Cellular senescence in aging and age-related disease: From mechanisms to therapy. <i>Nat Med<\/i> 2015; 21: 1424\u20131435.","DOI":"10.1038\/nm.4000"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Xu M, Tchkonia T, Ding H, Ogrodnik M, Lubbers ER, Pirtskhalava T, et al. JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. <i>Proc Natl Acad Sci USA<\/i> 2015; 112: E6301\u2013E6310.","DOI":"10.1073\/pnas.1515386112"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/11\/84_CJ-20-0703\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T03:27:45Z","timestamp":1603510065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/84\/11\/84_CJ-20-0703\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,23]]},"references-count":56,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-20-0703","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,23]]}}}